Hanmi Pharm signs $2.3 bil. licensing deal with Roche's Genentech for obesity drug candidate
Hanmi Pharm, a Korean pharmaceutical company, said Monday it has signed a 3.2 trillion-won ($2.3 billion) licensing deal with Genentech, a U.S.-based member of the Roche Group, for an obesity drug candidate designed to reduce body fat while preserving and increasing muscle mass. Hanmi Pharm has signed an exclusive licensing agreement with Genentech for the development, manufacturing and…
Korean pharmaceutical company Hanmi Pharm has entered into a $2.3 billion licensing agreement with Genentech, a member of the Roche Group, for an obesity drug candidate. The agreement grants Genentech exclusive rights to research, develop, manufacture, and commercialize the drug candidate, HM17321, worldwide, excluding Korea. Hanmi retains the rights to the drug in Korea.
HM17321 is a long-acting analog of uro-cortin-2 (UCN2) designed to reduce body fat while preserving and increasing muscle mass. The drug candidate is intended to treat obesity and related conditions, such as type 2 diabetes. Roche and Genentech aim to offer a differentiated approach to selectively reduce fat mass while improving muscle mass and function with this next-generation investigational therapy.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Hanmi Licenses Obesity Drug To Genentech businesskorea.co.kr
- Hanmi Pharm signs $2.3 bil. licensing deal with Roche's Genentech for obesity drug candidate koreatimes.co.kr
- Hanmi Pharm shares jump 30% on Genentech obesity drug deal investing.com
- Roche bets up to $2.3B on Hanmi’s early-stage muscle-building obesity asset endpoints.news
- Hanmi Pharm signs 3.2 tln-won licensing deal with Roche's Genentech for obesity drug candidate en.yna.co.kr
